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Abstract: Lead (Pb) exposure remains a major concern in the United States (US) and around the
world, even following the removal of Pb from gasoline and other products. Environmental Pb
exposures from aging infrastructure and housing stock are of particular concern to pregnant women,
children, and other vulnerable populations. Exposures during sensitive periods of development
are known to influence epigenetic modifications which are thought to be one mechanism of the
Developmental Origins of Health and Disease (DOHaD) paradigm. To gain insights into early life Pb
exposure-induced health risks, we leveraged neonatal dried bloodspots in a cohort of children from
Michigan, US to examine associations between blood Pb levels and concomitant DNA methylation
profiles (n = 96). DNA methylation analysis was conducted via the Infinium MethylationEPIC array
and Pb levels were assessed via high resolution inductively coupled plasma mass spectrometry
(HR-ICP-MS). While at-birth Pb exposure levels were relatively low (average 0.78 µg/dL, maximum
of 5.27 ug/dL), we identified associations between DNA methylation and Pb at 33 CpG sites, with the
majority (82%) exhibiting reduced methylation with increasing Pb exposure (q < 0.2). Biological
pathways related to development and neurological function were enriched amongst top differentially
methylated genes by p-value. In addition to increases/decreases in methylation, we also demonstrate
that Pb exposure is related to increased variability in DNA methylation at 16 CpG sites. More work is
needed to assess the accuracy and precision of metals assessment using bloodspots, but this study
highlights the utility of this unique resource to enhance environmental epigenetics research around
the world.
Keywords: exposure assessment; epigenomics; neonatal bloodspots; metals; developmental origins
of health and disease; biomarkers
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1. Introduction
Even with recent reductions in lead (Pb) exposure [1], Pb toxicity and related health effects
remain a concern in nearly every country around the world. According to the Housing and Urban
Development’s American Healthy Homes Survey, which uses the United States (US) data from 2005
and 2006, almost a quarter of all US homes are estimated to have multiple Pb-based paint hazards [2].
There are also mounting concerns about the risk of exposure to Pb due to the aging infrastructure.
The Flint, Michigan water crisis was one publicized example of contamination from failed Pb pipes [3],
and recent evaluations of US drinking water revealed other cities with similar problems [4]. In low- and
middle-income countries (LMICs), Pb exposure occurs through various contamination sources including
Pb-acid battery production and recycling, Pb-glazed ceramics, and limited uses of leaded-gasoline [5,6].
While the scientific consensus is that there is no safe level of Pb, a considerable amount of research
has been devoted to understanding the impact of Pb exposure at or around the blood Pb reference
value of 5 µg/dL, especially in the early stages of development [7]. Pregnant women and children are
among the most vulnerable to Pb exposure, which is known to be especially toxic during periods of
rapid growth [8], and it has been postulated that epigenetic perturbations by perinatal environmental
exposures such as Pb could have persistent health effects throughout life [9]. For children, early life
exposure can occur in utero via placental transfer, in infancy through breast milk, and directly from
the drinking water and other sources (e.g., soil, peeling paint or Pb dust in older homes) throughout
childhood. Such exposures may disproportionately affect susceptible populations, including pregnant
women, children, and racial or ethnic minority groups that experience disparities in access to healthy
housing or clean drinking water [10].
At the interface between environment and inherited genetics lies epigenetics—a suite of molecular
mechanisms that give rise to a pseudo-Lamarckian [11] intra-organism adaptability. Epigenetics is the
study of chemical modifications to DNA or chromatin, which can be passed from one cell generation
to the next influencing gene expression without altering the underlying DNA sequence, and with such
modifications remaining potentially reversible throughout the life-course [12]. Although epigenetic
modifications are natural and necessary, aberrant patterns at both the gene and genome-wide level
have been linked to many chronic health conditions including metabolic diseases [13], cancer [14],
and Alzheimer’s disease [15]. Epigenetics is thought to be one biological mechanism underlying the
developmental origins of health and disease (DOHaD) hypothesis, which postulates that early-life
exposures can impact later-life health outcomes [16]. Accordingly, toxicant exposure during periods of
rapid growth (e.g., embryogenesis), when the epigenome is being patterned and fidelity is paramount,
could cause deregulation of gene expression and increase the risk of disease [17].
The toxicity of Pb is best known in the context of neurological-related outcomes, but data from
recent animal and human studies corroborate the DOHaD theory and suggest a potentially broader
impact of Pb exposure with sex-specific associations with other health outcomes such as adiposity and
cardiometabolic risk in animal [18,19] and human studies [20,21]. These long-lasting, wide-spread
effects of Pb exposure could be explained in part by the influence of Pb on epigenetic marks. Increasingly,
evidence suggests gestational Pb exposure influences offspring epigenetic programming in mouse
and human studies utilizing candidate-gene [18,22,23] or epigenome-wide approaches [8,24–26] to
assess DNA methylation. Epigenome-wide DNA methylation platforms can help to identify candidate
gene pathways that shed light on the impact of Pb on development processes and later-in-life risk for
neurological, cardiovascular, or other adverse health outcomes.
Understanding the early-life exposome and the short- and long-term impact it exerts on offspring
health hinges on the availability of relevant exposure and outcome data. In a traditional cohort
study model, this would be limited to the number of participants recruited, successfully sampled and
followed prospectively. Neonatal bloodspots offer a unique opportunity in that the sample is collected
from nearly all children at birth in many countries, with the caveats that not all states/countries
retain bloodspots, some parents refuse collection or storage, and some storage programs may have
started after the population of interest was born. As of 2011, 20 states in the US retained bloodspots
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to be used for research purposes, though procurement and storage processes vary widely between
states [27]. Increasing interest in genetic and epigenetic studies utilizing bloodspots has generated
much controversy, and guidance for researchers have been discussed in this context for the US [28] and
globally [29]. Despite these difficulties, bloodspots represent a unique and precious resource that needs
to be handled with care, both physically and ethically. Our study is just one example of the broad
applications bloodspots have in expanding our understanding related to environmental influence on
health and disease.
In this study, we hypothesize that gestational Pb exposure will be associated with newborn
DNA methylation profiles and that we can assess both Pb levels and DNA methylation via neonatal
bloodspots. To test this hypothesis, we leveraged a study of mother–child pairs with archived neonatal
bloodspots, the Healthy Families (HF) Project [30]. The HF study has been leveraged previously
to study gene-specific epigenetics in relation to health status [31]; however, here we used archived
bloodspots to study at-birth epigenome-wide profiles among the participants in relation to gestational
toxicant exposure. Specifically, we measured Pb in neonatal bloodspots as a proxy measure of late
gestational exposure and measured genome-wide DNA methylation via the Infinium MethylationEPIC
array in the same bloodspots.
2. Materials and Methods
2.1. Healthy Families Project
In order to examine health outcomes in children across sensitive developmental periods, the HF
project recruited 40 families with children 12–24 months old (toddlers), 40 families with children
3–5.99 years old (preschool), and 52 families with children 10–12.99 years old (school-aged) within 1-h
driving distance to Ann Arbor, Michigan, US. During a home visit by a research assistant, families
provided survey data, child and parent anthropometric measurements, and written, informed consent.
Questionnaires were used to assess sociodemographic characteristics, which included measures of
maternal education, child race/ethnicity, and child sex. Methods and details on the original study were
previously detailed [31]. While the HF project originally focused on health and behavior of children
and their families, we leveraged data and archived samples from this study population to estimate
gestational exposure to Pb and assess its impact on the child’s epigenome at birth. To do so, we selected
a subset of HF participants from all recruitment age-groups with archived neonatal bloodspots for
inclusion (Figure 1).
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Figure 1. Participant inclusion flowchart for Pb analysis and DNA methylation analysis.
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2.2. Neonatal Bloodspots
The US state of Michigan has collected and archived neonatal bloodspot samples from most
children born in the state since 1984. These samples are collected via heel prick in the hospital within
24 h of birth and are used for genetic screening of rare disorders. The remaining bloodspots are stored
at the Michigan Neonatal Biobank where they can be accessed with proper consent. For recruited
participants with neonatal bloodspots available (see Figure 1), specimens were sourced from the
Michigan Neonatal Biobank. Consent was obtained from all recruited families prior to bloodspot
procurement. Michigan Department of Health and Human Services (MDHHS) and University of
Michigan (UM) IRB approvals were obtained for the Healthy Families project (UM: HUM00079730)
and DNA isolations from neonatal bloodspots (MDHHS: 201311–04-EA). Before retrieval, Michigan
Neonatal Biobank bloodspots were stored at different temperatures depending upon their collection
date. As such, the current age of each recruited child corresponded to the storage method for their
bloodspot: toddler and preschooler bloodspots were stored at−20 ◦C, school-aged children’s bloodspots
were stored at 20 ◦C. Upon receiving the bloodspots for use in epigenetic analyses, they were stored in
sealed bags at 4 ◦C.
2.3. Bloodspot Pb Assessment
All supplies were acid-cleaned, and bloodspot samples were processed and analyzed in Class 100
and 1000 ultraclean rooms at the Michigan State University Exposure Science Laboratory. Two bloodspot
punches per sample were excised using a 3-mm sterile biopsy punch. In order to assess background
levels of Pb in blank filter card material, two blank 3-mm punches next to each bloodspot were also
excised. Each 3-mm bloodspot punch was assumed to contain 3.1 µL of blood based on previous
studies [32,33]. Each punched sample was transferred to an acid-cleaned centrifuge tube using
Teflon-coated tweezers, and 3 mL of extraction solution (5% ultrapure grade HNO3, and 0.05% Triton
X-100 in Type I water) was added. The solutions were centrifuged at 3600× g (6200 rpm) for 2 min
and then incubated for 90 min at room temperature on a shaker table at 300 rpm. Extracts were then
analyzed for Pb using high-resolution inductively coupled plasma-mass spectrometry (HR-ICP-MS,
ELEMENT2, Thermo Finnigan, San Jose, CA, USA). Five-point calibration curves were created using
Pb standards (SPEX CertiPrep, Metuchen, NJ, USA) in 5% nitric acid solution. National Institute
of Standards and Technology (NIST, Gaithersburg, MD, USA) SRM 1640a was used as an external
quality control standard to check the calibration of the instrument, and NIST SRM 955c caprine blood
was used to assess the recovery and accuracy of the sample digestion and analysis by spiking blank
Whatman #903 Protein Saver cards. This analysis method incorporates daily quality assurance and
quality control measures including field blanks, Type I water blanks, replicate analyses and external
standards as described elsewhere [34,35]. The method detection limit (MDL) for Pb was determined to
be 0.07 µg/dL.
2.4. DNA Isolation
DNA was isolated from neonatal bloodspots using a modified version of the QIAamp DNA Micro
Kit (Qiagen, Cat. #56304, Hilden, Germany). To maximize DNA yields from bloodspots, a number of
changes were made to the standard QIAamp DNA Micro Kit protocol. First, isolations were performed
on four 3mm bloodspot punches rather than the recommended three punches. Second, to ensure
complete digestion, the heated incubation step was increased from 1 h to 2 h. Third, the digested
solution containing lysis buffer and bloodspot punch material were transferred to a spin basket
(Qiagen Cat# 19598) over a collection tube before first spin. DNA was eluted with nucleic acid free
water heated to 70 ◦C in a two-step process, first with 45 µL followed by 30 µL, each with a 5-min
incubation before spinning. Across all bloodspot samples (n = 129), average DNA yield (SD) was
2.1 µg DNA (SD = 0.6 µg).
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2.5. MethylationEPIC Analysis
Quality control and DNA methylation analysis via the Infinium MethylationEPIC occurred at the
University of Michigan Epigenomics and Advanced Genomics Cores following standard procedures.
Briefly, the Qubit high sensitivity double stranded DNA assay was used to quantify DNA. For a subset
of 96 samples (see Figure 1), 250 ng were bisulfite converted with the EZ DNA Methylation kit (Zymo)
using the manufacturer’s incubation parameters specific for Illumina arrays. Samples were hybridized
to the Infinium MethylationEPIC BeadChip and scanned at the Advanced Genomics Core. Raw image
files were then read into R using the minfi Bioconductor package [36]. Quality control was performed
using the Enmix Bioconductor package. Quality control procedures include examining data for outlier
samples, (with low intensity overall and/or by overall distribution of methylation across all probes),
removing poorly performing samples (with estimated sex mismatch or with >5% of probes with
low detection), and removing poorly performing probes (detection p-value > 0.05 in at least 5% of
samples [37]. Additionally, probes from the X and Y chromosomes, cross-reactive probes, and probes
with polymorphisms in the CpG site were excluded. All samples passed quality control, and 789,147
probes were retained for analysis. Probe intensities were corrected for background and dye bias [36].
Probes were annotated using the ilm10b4.h19 annotation R package, which includes genomic locations
and features (gene name, regulatory regions, evidence for each locus being in an enhancer, DNAseI
hypersensity site, etc.).
2.6. Statistical Methods
All statistical analyses were performed in the R Software for Statistical Computing. We first
calculated descriptive statistics on neonatal bloodspot Pb concentrations and all covariates, and assessed
distributions of continuous variables. We estimated cell-type proportions from each sample using
an algorithm based on Infinium data and a reference dataset from sorted cord blood cells [38,39].
We performed analyses (Spearman correlations and ANOVA tests) to identify covariates associated
with Pb (i.e., potential confounders) from among: technical factors (EPIC chip and chip position),
estimated cord blood cell-type proportions (nucleated red blood cells (nRBCs), CD4+ T-cells, CD8+
T-cells, B cells, monocytes, granulocytes, and natural killer cells), maternal (BMI, race [white vs.
all other], education) and child characteristics (sex, age group). None were significantly associated
with neonatal Pb levels at p < 0.05. We next used the R package ChAMP to perform singular value
decomposition to identify technical or biological covariates associated with principal components of the
entire DNA methylation dataset [40]. In this analysis, a Kruskal–Wallis test for categorical covariates
or a linear model for continuous covariates were used to test associations between covariates and each
of the principal components of the DNA methylation beta matrix. Race, child’s sex, recruitment group,
and cell type estimates were associated with the first four principal components of DNA methylation.
We used least squares regression to identify differentially methylated CpG sites (using beta values
for each of 789,147 CpG sites as the outcomes) associated with Pb exposure. We used an empirical
Bayes model to moderate the standard errors and determine a significance value for each model in the
limma package [41]. While none of the available covariates had evidence for confounding (associated
with both Pb and DNA methylation data), we included sex, race, and estimated cell-type proportions
(granulocytes, nucleated red blood cells, B cells and monocytes) as covariates in the final models
due to their highly significant associations with DNA methylation profiles in this study. We did not
include recruitment group as we found it to be confounded by cell-type proportions (Supplementary
Table S1). We also report results for a model excluding cell type estimates adjusting only for sex and
race. The association with Pb was tested first using neonatal Pb as a continuous variable (in µg/dL).
In the continuous Pb analysis, values below the MDL were set to MDL/sqrt (2). Since 16% of the
values were below the MDL, we also tested the association with Pb as a dichotomous variable, splitting
samples equally into two groups (above and below the median of 0.55 µg/dL).
We considered p < 9 × 10−8, the p-value recommended for MethylationEPIC studies based on
the number of multiple comparisons taking into account the correlation between some loci on the
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array [42], as the strongest evidence for a statistically significant association between Pb and DNA
methylation at each locus. Given our small sample size and limited statistical power, we also discuss
results as potential avenues for future exploration with false discovery rate q-value < 0.2. In addition
to site-specific analyses, we identified differentially methylated regions (DMRs; regions consisting
of two or more neighboring CpG sites that were associated with Pb exposure, using an algorithm
called DMRcate [43]. In the DMRcate analysis, the Gaussian kernel bandwidth was set to 1000 with
a smoothing function of C = 2. We also assessed whether any biological pathways were enriched
amongst the top 10,000 CpG sites (by raw p-values ranging from 1.33 × 10−6 to 0.014; [44]). For the
association with continuous and categorical Pb measures using a gene ontology enrichment algorithm
designed for Infinium data that adjusts for the number of CpG sites within each gene represented on
the array [44]. This analysis was run for Gene Ontology (GO) and KEGG pathways, and results with
an FDR adjusted value of q < 0.2 are discussed.
Whereas the methods listed above assess the influence of Pb on increases or decreases DNA
methylation at a given site, toxicant-induced increases in DNA methylation variability have also been
hypothesized [45]. Thus, we utilized DiffVar, a function in the missMethyl Bioconductor R package to
test for Pb-related changes in DNA methylation variability. This method is based off of Levene’s z-test,
and involves performing a t-test on the absolute deviations of the M-values (logit-transformed beta
values) from the group mean to test the null hypothesis that group variances are equal. An empirical
Bayes framework is then used to moderate the t-statistics prior to significance calling. This method is
robust against non-normality and outliers [44,46]. We performed this analysis using a model adjusting
for cell-type proportions, sex, and race.
3. Results
3.1. Cohort Characteristics
Mothers recruited to the HF study (n = 129) were 77% white and had an average BMI of 29.3 kg/m2
± 8.8 standard deviation. The children who participated were 54% male and the proportions across the
three age groups of toddlers, preschool-age and school-aged were 30%, 26% and 44%, respectively
(see Table 1). Children and their mothers from the subset selected for EPIC analysis were not
significantly different from families from the HF study overall.
3.2. Sample Characteristics
This study utilized neonatal dried bloodspots that were archived by the State of Michigan and
underwent different storage conditions and storage time depending on the participant recruitment
group. In group 1 (n = 40), samples were stored at −20 ◦C for approximately 5 years (see Figure 1).
In group 2 (n = 39), samples were stored at−20 ◦C for approximately 8 years. In group 3 (n = 50), samples
were stored at room temperature for approximately 16 years. Despite the varying storage conditions,
we demonstrated that DNA of adequate quality and quantity could be extracted from four 3-mm
punches, undergo bisulfite conversion, and pass all quality control checks included in the Infinium
MethylationEPIC pipeline for all three groups. When completing the singular value decomposition
(SVD) analysis, we noted that the sample group was associated with principal components 1, 3,
and 7 of the DNA methylation data (p < 0.05; Figure S1). In bivariate analysis, we noted that the
association between the recruitment group and DNA methylation was largely confounded by cell-type
distributions. Table S1 displays the mean estimated cord blood cell-type proportions by the recruitment
group. In the third group of children ages 10–12 years, estimated proportions of nRBCs and CD8+
T-cells were significantly higher than in samples from the other two age groups (ANOVA p < 0.01).
Since cell-type proportions are a known strong predictor of variation in DNA methylation, we included
cell-type estimates instead of the sample group in final statistical models.
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Table 1. Cohort Characteristics and Pb Exposure Assessment.
Included in MethylationEPIC
Analysis, n = 96 All HF Families, n = 129
Characteristics Mean ± SD or N (%) Range Mean ± SD or N (%) Range
Mothers
BMI (kg/m2) 29.3 ± 8.9 15.4–66.4 29.5 ± 8.8 15.3–66.4
Obesity
Not obese 60 (63%) 77 (60%)
Obese 34 (35%) 55 (39%)
Race
Non-white 22 (23%) 29 (22%)
White 74 (77%) 99 (77%)
Children
Male (%) 52 (54%) 69 (53%)
Recruitment Group
Group 1 29 (30%) 40 (31%)
Group 2 25 (26%) 39 (30%)
Group 3 42 (44%) 50 (39%)
Estimated Cord Blood
Cell Type %
Nucleated Red Blood Cells (nRBC) 4.2 ± 2.0 0.5–12.8 na na
CD8+ T cells 7.5 ± 3.4 2.3–23.6 na na
CD4+ T cells 19.3 ± 6.5 6.6–43.5 na na
B cells 6.1 ± 2.8 1.4–21.0 na na
Monocytes 9.0 ± 2.3 4.1–17.9 na na
Granulocytes 57.0 ± 10.4 17.5–77.1 na na
Natural Killer Cells 0.01 ± 0.1 0–0.96 na na
Pb Exposure Assessment
Blood spot Pb (µg/dL) 0.78 ± 0.85 <MDL–5.27 0.93 ± 0.80 <MDL–5.27
Pb Category
Low (<median 0.55 µg/dL) 48 (50%) 69 (53%)
High (≥median 0.55 µg/dL) 48 (50%) 60 (47%)
Note, 2 moms are missing BMI. In the full study sample, 128 have data on race (1 is missing). SD, standard deviation;
na, not applicable; MDL, method detection limit. Group 1, children 12–24 months old at time of recruitment;
Group 2, children 3–5.99 years old; and Group 3, children 10–12.99 years old.
3.3. Pb Assessment in Dried Bloodspots
Pb levels were detectable in all bloodspot samples and blank filter card samples. Exposure levels
reported in this paper were calculated by subtracting Pb levels of each blank filter card sample from its
corresponding bloodspot sample. The average Pb concentrations in blank filter card samples and in
uncorrected bloodspot samples were 1.31 ± 0.59 µg/dL and 2.25 ± 1.02 µg/dL, respectively. After blank
correction, bloodspot sample Pb concentrations ranged from <MDL to 5.27 µg/dL with a median
concentration of 0.55 µg/dL. Twenty-one corrected samples (16%) were below the MDL.
3.4. CpG Site Loci and Regions Differentially Methylated by Pb
In the site-specific analysis of 789,147 CpG sites, we identified a number of genes with differential
methylation by levels of Pb exposure. In the model without cell-type adjustment and including Pb
concentration as a continuous variable, we observed 30 CpG sites that showed decreasing methylation
and 3 CpG sites that showed increasing methylation with increasing Pb exposure. For this analysis,
we used a p-value cutoff recommended for epigenome-wide studies that use the MethylationEPIC
array (p < 9 × 10−8; Table S2). Given the small sample size, we also report CpG sites significant at an
FDR q-value < 0.2 for the exploration of potential associations with exposure in future studies. In the
same model without cell-type adjustment, we observed 99 and 23 CpG sites that showed decreasing
and increasing methylation, respectively, with Pb exposure at a relaxed q < 0.2. Out of these sites,
66% were in DNAseI hypersensitivity sites, 9% were in transcription factor binding sites, 11.5% were
in CpG islands, and 18% were in suspected or known enhancers.
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Given the broad influence of cell-type distribution on DNA methylation profiles, we next adjusted
for cell-type proportions and did not observe any CpG sites associated with Pb as a continuous variable
at p < 9 × 10−8. Table 2 displays results for the 32 CpG sites associated with Pb at q < 0.2 (27 decreasing
and 5 increasing) after adjusting for cell types. Many of these sites were in at least one known or
expected regulatory region including six (19%) in CpG islands, three (9%) in transcription factor
binding sites, 19 (59%) in DNAseI hypersensitivity sites, and seven (22%) in enhancers. Thirty of the
thirty-two loci in the cell-adjusted model were also significant in the cell-free model.
Table 2. Differentially Methylated CpG Sites by Pb (q < 0.2).
Probe ID Position GeneName
Relationship
to CpG Island
Estimate
(per ug/dL Pb)
SE of
Estimate
Average %
Methylation at
the CpG Site
Raw
p-Value q-Value
cg03744954 chr7:23637556 CCDC126 Island 0.010 0.002 2.2% 1.33 × 10−6 0.12
cg11961702 chr10:1130138 WDR37 Open Sea −0.007 0.001 98.1% 1.08 × 10−6 0.12
cg09489281 chr5:43604149 NNT S. Shore 0.027 0.005 5.1% 1.19 × 10−6 0.12
cg06157837 chr16:50130934 HEATR3 Open Sea −0.021 0.004 92.7% 1.08 × 10−6 0.12
cg12819470 chr7:18013541 Open Sea −0.022 0.004 94.1% 1.34 × 10−6 0.12
cg00694932 chr22:49029825 FAM19A5 Open Sea −0.027 0.005 87.6% 4.91 × 10−7 0.12
cg12666827 chr17:81043176 METRNL Island −0.026 0.005 92.1% 5.19 × 10−7 0.12
cg17533118 chr2:204664739 Open Sea −0.030 0.006 88.3% 8.35 × 10−7 0.12
cg16393928 chr1:3135836 PRDM16 Open Sea −0.024 0.005 90.8% 1.46 × 10−6 0.12
cg27500206 chr11:4600140 C11orf40 Open Sea −0.031 0.006 90.8% 7.93 × 10−7 0.12
cg25968149 chr3:174255312 Open Sea −0.020 0.004 92.9% 1.80 × 10−6 0.12
cg20383654 chr1:39490535 NDUFS5 Open Sea −0.018 0.004 93.0% 1.82 × 10−6 0.12
cg05355328 chr19:33096524 ANKRD27 Island −0.022 0.004 94.2% 1.98 × 10−6 0.12
cg25104648 chr18:18566146 ROCK1 Open Sea −0.022 0.004 95.0% 2.57 × 10−6 0.13
cg08236836 chr2:95613608 Open Sea −0.017 0.003 98.4% 2.54 × 10−6 0.13
cg25198485 chr4:58086247 Open Sea −0.021 0.004 92.2% 2.46 × 10−6 0.13
cg23724374 chr6:150973466 PLEKHG1 Open Sea −0.019 0.004 89.7% 3.37 × 10−6 0.15
cg11877273 chr1:29182535 OPRD1 Open Sea −0.019 0.004 94.1% 3.61 × 10−6 0.15
cg06019448 chr4:190417346 Open Sea −0.023 0.005 90.5% 3.53 × 10−6 0.15
cg06051201 chr1:53925306 DMRTB1 Island −0.026 0.005 95.1% 4.37 × 10−6 0.17
cg09980056 chr6:52366854 TRAM2 Open Sea −0.025 0.005 95.0% 4.60 × 10−6 0.17
cg09413029 chr10:97152467 SORBS1 Open Sea −0.022 0.005 93.0% 4.49 × 10−6 0.17
cg14810301 chr5:88169099 MEF2C Open Sea −0.018 0.004 93.3% 5.41 × 10−6 0.17
cg15406566 chr16:4606279 C16orf96 Open Sea 0.011 0.002 87.4% 5.55 × 10−6 0.17
cg05026437 chr3:99527476 MIR548G Open Sea −0.021 0.004 92.5% 5.44 × 10−6 0.17
cg14645844 chr8:123831620 ZHX2 Open Sea -0.024 0.005 93.7% 5.17 × 10−6 0.17
cg10174926 chr14:72818968 RGS6 Open Sea −0.018 0.004 93.0% 5.81 × 10−6 0.17
cg07431286 chr5:72526496 Island 0.003 0.001 3.1% 6.04 × 10−6 0.17
cg27094173 chr11:73371753 PLEKHB1 N. Shore −0.008 0.002 92.9% 7.49 × 10−6 0.20
cg00394874 chr6:30747276 Open Sea 0.048 0.010 25.4% 7.85 × 10−6 0.20
cg06534673 chr16:1210311 CACNA1H Island −0.027 0.006 71.4% 7.73 × 10−6 0.20
cg07366047 chr2:135921205 RAB3GAP1 Open Sea −0.029 0.006 94.1% 7.97 × 10−6 0.20
We utilized DMRcate to identify regions with at least two neighboring CpG sites that were
associated with Pb in the same direction. We identified four regions with decreasing methylation at 3,
4, 8, and 17 CpG sites and two with increasing methylation at four CpG sites each (Table 3).
Since 16% of bloodspot samples fell below the MDL, we also assessed associations with DNA
methylation after categorizing Pb exposure. When dichotomizing Pb exposure into two groups by
median concentration (0.55 µg/dL), no CpG sites were significantly associated with the Pb group at
p < 9 × 10−8 or at q < 0.2, whether or not cell proportions were included in the model. Based on these
results, we did not conduct DMR analysis for dichotomized Pb.
3.5. Biological Pathways Enriched for Differential Methylation by Pb
Six GO pathways were enriched amongst the 10,000 CpG sites with the lowest p-value for their
association with continuous Pb exposure (Table 4). Amongst these, four pathways involved in cell
morphogenesis and cellular adhesion were also enriched in the dichotomous Pb analysis. In total,
13 GO and two KEGG pathways were enriched amongst the top 10,000 CpG sites by dichotomous Pb.
These pathways included morphogenesis for cells and neuron projections, post-synapse organization,
cellular adhesion, axon guidance, and GABAergic synapses.
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Table 3. Differentially Methylated Regions (DMRs) by Pb Exposure.
Position Genes Overlapping This Region # of CpG Sites Mean Difference in ProportionMethylated per 1 µg/dL Pb
Min. Smoothed FDR
q-Value
chr19:33096524-33096688 ANKRD27 3 −0.006 3.15 × 10−6
chr1:53925145-53925368
snoU13, Y_RNA, SCARNA16, U1, SCARNA18,
SCARNA24, SNORD112, SNORA62,
SNORA63, SNORD46, DMRTB1, SNORA2,
SNORD81, U3, SNORA51, SNORA25,
SCARNA20, SNORA67, U6, SNORA70,
SNORA77, SNORA26, U8, SCARNA11,
SNORA31, SNORA42, SNORA40, SNORD64,
ACA64, snoU109, SNORD60, SNORD116
4 −0.020 2.12 × 10−6
chr9:123605229-123605666 PSMD5-AS1, PSMD5 8 −0.015 5.42 × 10−7
chr15:93616424-93617402 RGMA 17 −0.014 5.60 × 10−14
chr11:111637306-111637615 4 0.010 3.06 × 10−5
chr17:6796745-6797034 ALOX12P2, AC027763.2 4 0.016 6.21 × 10−5
These results are from the model adjusting for sex and race, with Pb as a continuous variable. Models adjusting for cell type did not have any significant DMRs. FDR, false discovery rate.
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Table 4. Enriched Biological Pathways by Top 10,000 Genes by p-value in Cell-type adjusted models.
Pathway Identifier Description of Pathway # of Genes inPathway
# Differentially
Methylated Genes p-Value q-Value
# Differentially
Methylated Genes p-Value q-Value
GO Analysis—Dichotomized Pb GO—Continuous Pb
GO: BP GO:0000902 cell morphogenesis 990 390 1.48 × 10−6 0.025 385 2.65 × 10−5 0.139
GO: BP GO:0000904 cell morphogenesis involved indifferentiation 709 292 2.24 × 10
−6 0.025 ns
GO: BP GO:0022610 biological adhesion 1369 467 5.47 × 10−6 0.034 472 1.23 × 10−5 0.131
GO: BP GO:0007155 cell adhesion 1363 465 5.93 × 10−6 0.034 469 1.73 × 10−5 0.131
GO: BP GO:0032989 cellular component morphogenesis 1098 417 1.03 × 10−5 0.047 421 9.31 × 10−6 0.131
GO: BP GO:0032990 cell part morphogenesis 653 269 1.25 × 10−5 0.047 ns
GO: BP GO:0048812 neuron projection morphogenesis 617 256 1.83 × 10−5 0.058 ns
GO: BP GO:0120039 plasma membrane bounded cellprojection morphogenesis 631 261 2.10 × 10
−5 0.058 ns
GO: BP GO:0048858 cell projection morphogenesis 635 262 2.30 × 10−5 0.058 ns
GO: BP GO:0048667 cell morphogenesis involved inneuron differentiation 555 234 3.05 × 10
−5 0.069 ns
GO: BP GO:0099173 postsynapse organization 150 72 6.64 × 10−5 0.136 ns
GO: BP GO:1902285 semaphorin-plexin signaling pathwayinvolved in neuron projection guidance 11 11 7.18 × 10
−5 0.136 ns
GO: CC GO:0071944 cell periphery 5163 1465 9.25 × 10−5 0.162 ns
GO: MF GO:0047372 acylglycerol lipase activity 9 ns 9 3.05 × 10−5 0.139
KEGG Analysis—Dichotomized Pb KEGG—Continuous Pb
KEGG path:hsa04360 Axon guidance 174 86 4.76 × 10−5 0.016 ns
KEGG path:hsa04727 GABAergic synapse 84 43 9.06 × 10−5 0.153 ns
GO = Gene Ontology; BP = Biological Process; CC = Cellular Component; MF = Molecular Function; KEGG = Kyoto Encyclopedia of Genes and Genomes; Pb = Lead; # = number; ns = not
significant (q > 0.2).
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3.6. Differential Variability by Pb Exposure
Exposure-induced changes that result in altered epigenetic programming or maintenance may
manifest as changes in mean methylation (i.e., presented in the differential methylation analysis),
or could instead result in more variability from increased stochasticity. With this in mind, we conducted
“DiffVar” analysis, an approach based on Levene’s z-test, to identify CpG sites with increasing or
decreasing variability with more Pb exposure. While no differentially variable CpG sites were detected
when modeling Pb as a dichotomous variable, 16 CpG sites had higher variability as continuous Pb
levels increased (q < 0.2), including two CpG sites at q < 0.05 after adjusting for cell-type proportions,
sex, and race (Table S3).
4. Discussion
In this study, we leveraged the State of Michigan’s Neonatal Biobank to access archived bloodspot
specimens and measure at-birth exposure to Pb as well as epigenetic patterns. While nearly all at-birth
specimens had a Pb measurement lower than the US CDC’s reference value of 5 µg/dL, we detected
differential DNA methylation by Pb exposure including increased variability at some CpG sites and
decreased or increased DNA methylation by exposure at others. The average and range of the Pb levels
measured here (average 0.78 µg/dL bloodspot Pb with a maximum of 5.27 µg/dL) are similar to levels
reported in the US according to the most recent National Health and Nutrition Examination Survey
(NHANES) [47], providing confidence in our technique. While this study is one of only a few to show
this in the context of bloodspot Pb levels, our data add to a growing body of evidence which suggests Pb
can influence epigenetic patterns. For example, the ELEMENT cohort study (n = 247) has linked early
life Pb exposure, which was measured in maternal bone, maternal blood, and cord blood, with early life
and peri-adolescent DNA methylation using candidate-gene methods [23,48,49]. As a second example,
Project Viva (n = 268), a US-based prebirth cohort, has also demonstrated that maternal blood Pb levels
during pregnancy are related to cord blood epigenome-wide DNA methylation patterns. In contrast to
the higher average in the Mexico-based ELEMENT study, Project Viva recorded an average erythrocyte
Pb level of 1.22 µg/dL ranging from 0.29–4.97, which is more in line with our participant exposures [26].
An additional Mexico City study showed that prenatal Pb (in addition to multiple other metals)
impacts cord blood DNA methylation at genes related to DNA repair [50]. Complementing this human
data, animal studies support the toxicoepigenetic impact of Pb. Perinatal Pb exposure in mice via
maternal drinking water has been shown to impact DNA methylation patterns at retrotransposons
in the brain [22], metastable epialleles in tail tip DNA [18] and promoters throughout the genome in
DNA from sorted cortical neurons [51]. These findings are consistent with other reports that that early
life Pb is related to murine DNA methylation patterns, and that the epigenetic effects of Pb exposure
may persist throughout life [52].
The differentially methylated genes in our study showed enrichment for biological pathways,
including cellular organization, neurodevelopment, and neurological function. In some ways, the latter
may be unsurprising given the known link between Pb exposure and neurodevelopment, but identifying
these relationships in infant bloodspots further bolsters the potential utility of this specimen and
highlights the potential impact of relatively low blood Pb levels during development. Cellular
organization terms were also common in a study that evaluated the hippocampal methylome of rats
developmentally exposed to Pb, in which the authors showed that rats in the lowest exposure group
had the most overrepresented GO terms compared to the control group [53]. This non-monotonic
relationship highlights the need to study low-level exposures. In addition to GO terms found in our
study, the identified differentially methylated CpG sites according to Pb levels on the MethylationEPIC
chip represent potential future avenues of research. For example, we showed decreased methylation at a
CpG site annotated to PRDM16 in Table 2. This same gene was recently identified in an epigenome-wide
study of Parkinson’s disease [54], which suggested epigenetic programming may contribute to this
disease and that postulated environmental exposures could induce the programming. Taken together
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with our findings, PRDM16 could be a candidate gene for studies evaluating the long-term impact of
early life metal exposure on neurodegeneration.
In addition to differential methylation, we identified sites of epigenomic variability that were
associated with early life Pb exposure. We previously advanced this concept in a contemporary
review [45]. The premise is that exposure can result in aberration to include deregulation of methylation
and increased variability, with the latter resulting from increased stochasticity. We coined the phrase
“environmental deflection” to denote the exposure-induced change from a normal epigenetic profile
over time as well as the possible increased vulnerability of younger organisms to exposure relative to
older. The list of genes identified in our study as more variably methylated in relation to increasing
Pb exposure may be interesting targets for future research. For example, Ferredoxin 1 (FDX1) is
involved in adrenal steroidogenesis as well as bile acid and vitamin D synthesis [55]. The dysregulation
of iron–sulfur cluster genes, like FDX1, are known to cause human disease (e.g., infant multiple
mitochondrial malfunctions syndrome and infant multiple mitochondrial malfunctions syndrome [56])
and thus exposure-induced epigenetic variability at this locus warrants further study.
In this study, we utilized bloodspots to gain valuable insights into the early life environment and
its influence on the at-birth epigenome in a study population who were 1–13 years of age at recruitment.
Bloodspots have been successfully used to determine early life exposures including Vitamin D [57],
perfluorinated chemicals [58], and endocrine-disrupting chemicals [59]. Similarly, bloodspots have
been used to evaluate outcome measures such as immune function [60,61], thyroid hormones [62] and
insulin concentration [63]. Epigenome-wide and targeted patterns have also been assessed recently
using bloodspots. Gao et al. conducted an epigenome-wide analysis using the HumanMethylation
450 array (a predecessor to the MethylationEPIC array) on infant bloodspot specimens and identified
a relationship between the epigenetic pattern of a gene known to play a role in asthma and the risk
of wheeze by age six [64]. Another group evaluated bloodspot DNA methylation profiles using the
HumanMethylation 450 array and found evidence that gestational folic acid deficiency may influence
risk for cleft palate through an epigenetic mechanism [65]. The HF study children have been previously
studied, and bloodspots were used to assess gene-specific DNA methylation (via pyrosequencing) and
relate at-birth profiles with childhood weight status [31]. The use of archived samples, both in the
present study and in the research mentioned above, allows for a unique retrospective exposure and
epigenetic assessment in newly recruited study participants.
There is growing interest in metal exposure assessment via bloodspots in various environmental
health and public health studies due to the relatively non-invasive nature of blood sample collection.
For example, Basu and colleagues at McGill University have published on mercury assessment using
bloodspots in both wildlife [66] and human infant samples [32,67] and Ruden and colleagues at
Wayne State University have published on Pb assessment as well as DNA methylation analysis using
bloodspots. In line with our findings, Sen et al. demonstrated in a cohort of 45 children that Pb levels in
early childhood are associated with differential DNA methylation patterns at that same timepoint [25].
This same group has also investigated the multigenerational influence of at-birth Pb levels on the
epigenome using bloodspots from mother–infant pairs [68]. Combined with our results, these data
suggest that developmental Pb exposure can impact the programming of DNA modifications early in
life. It should be noted however that the precision and accuracy of bloodspot sample analysis are still
being evaluated [69–71]. For example, Funk et al. reported that blank blood collection cards contained
significant Pb concentrations and suggested that blank collection cards be cleaned before their use [72].
Our Pb bloodspot data also support their findings in that more accurate measurements can be obtained
by accounting for the Pb content of blank collection cards.
While leveraging archived bloodspots has the potential to accelerate the discovery of epigenetic
biomarkers and advance environmental epigenetic research, storage conditions (e.g., time and
temperature) may impact results. A recent study compared data quality and results for associations
between smoking or age and DNA methylation from the Infinium 450 array, run with matched samples
from 62 adults. One sample was stored in an EDTA-tube before DNA extraction while the other
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sample was spotted on a Whatman FTA card and stored at room temperature for 5–10 years before
extraction. Importantly, DNA methylation profiles from the two sample types were highly correlated
and produced similar results for the association studies without moderation by storage type [73].
Whether neonatal bloodspot samples are also robust against storage conditions, including storage for
longer than 10 years, is in need of full assessment. In our study, estimated proportions of CD8+ T-cells
and nRBCs were significantly higher in samples from the oldest recruited group; these samples had the
longest time in storage prior to DNA isolation and storage occurred at room temperature instead of in
a freezer. Whether these differences in storage conditions impacted the amount of DNA that survived
from various cell types should be tested experimentally. In the meantime, adjustment for cell-type
proportions is imperative when working with epigenetic data from bloodspots.
Our study highlights the utility of infant bloodspots and adds to a growing number of studies
using this specimen to assess at-birth exposures. However, we do acknowledge several limitations.
First, while we leveraged bloodspots as a way to retrospectively sample participants, future studies
will need to consider tissue from target tissues. Second, due to the small sample size, we had limited
statistical power to detect all true associations between Pb and DNA methylation, especially at CpG
sites with small effect sizes. We were also unable to perform sex-stratified analyses due to sample
size. Third, results from the present analysis may not be generalizable to populations with different
levels of exposure or racial/ethnic distributions. Finally, we recognize that the cross-sectional nature
of the exposure and DNA methylation measurements represent a unique strategy in the context of
bloodspots, but future studies should consider serial blood (or target tissue) assessment to more fully
characterize the exposure to Pb and its impact on DNA methylation profiles over time (incidence and
persistence of alteration).
5. Conclusions
In this US-based study, we leveraged dried bloodspots from birth to report on neonatal Pb
exposure and capillary blood leukocyte DNA methylation. While our cohort’s median bloodspot Pb
levels were relatively low, we were able to identify associations between DNA methylation and Pb at 32
CpG sites, with the majority being inversely associated with Pb concentrations. Our pathway analysis
suggests that low-level Pb exposure is related to development and neurological function. We also
demonstrate further evidence of phenomena we call environmental deflection in which developmental
exposure induces not only altered average methylation but also increased variability among those with
higher Pb exposure. This study also serves to highlight the utility of bloodspots as a source of at-birth
exposure and outcome data. By combining thoughtful collection and storage of bloodspot specimens
by local authorities and ethical stewardship by researchers, environmental epigenetic studies around
the world that aim to better understand exposure-induced disease would be enhanced with this unique
biological sample.
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